Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13782)	6/3/2000 8:34:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Blue, your love is dangerous: "why did your beloved FDA say the evidence is compelling? " Now, where did in the rejection letter to xoma that statement come from? this is just plain lunacy on your part, this was an alleged coment from ceoperson at the annual meeting and you are twisting it as from the FDA? Love da fantasy! My trading is not the issue and I do not blame company, but my trading does not exonerate the company poor behavior . You are more informed about my very neutral position to the company than that, of course DNA has competition and a $1 billion in revenues, Chir has it and a $1B in cash, so does Amgn and Bgen, and they do have other products, xoma has ZERO, except selling shares. But it is easy for you to vociferously argue my trading (which you do not have a piece of evidence to evaluate)instead of arguing the clear projections, numbers, calculations, and prospects of the ISSUE aka xoma. You never argue when Gw talks about $100M and $50M future indications. Youn never question Rk many references to all the "rest of the technology" You never question the now 50 million shares, and the coming 50 million, maybe you gracefully vote for the increase to 100 million, no a problem for you. Everything is perfect in xomaland, xombies are now asking for data, NOW? when is not worth a dime to know the failure numbers? Do you think the Street took $600M off marketcap out of xoma cause the FDA news is great? Wow!! Data now, when ceoperson allegedly was talking about more support, more data aka trials, next fall/winter, and NO approvals this year? Well, it is clear that my hogwash can not clean the pig. Your alleged profits are ceremoniously celebrated by me, congratulations, but please, present xome caveat when you are so gratuitously (or so I think)present the rosy picture of coma, I mean xoma.